Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report
- 1 October 2024
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400047
Abstract
Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is approved for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) tumors regardless of histology, there is a paucity of data to support its effectiveness in dMMR/MSI-H sarcomas. This study presents a case of a metastatic undifferentiated pleomorphic sarcoma of the retroperitoneum with dMMR status demonstrating a sustained complete response to pembrolizumab. Our case revealed inconsistencies in identifying dMMR/MSI-H status through next-generation sequencing, immunohistochemistry, and polymerase chain reaction methods. Therefore, we conducted a systematic review to analyze various methods for assessing dMMR/MSI-H and to explore whether pembrolizumab's indications rely on this biomarker.Keywords
This publication has 85 references indexed in Scilit:
- Concordance in detection of microsatellite instability by PCR and NGS in routinely processed tumor specimens of several cancer typesCancer Medicine, 2023
- Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyCancer, 2022
- Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patientsCancer Medicine, 2022
- Systemic treatments and outcomes in CIC‐rearranged Sarcoma: A national multi‐centre clinicopathological series and literature reviewCancer Medicine, 2022
- Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targetsGenes, Chromosomes and Cancer, 2021
- PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcomaCancer Reports, 2020
- Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive SarcomaJAMA Oncology, 2020
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With PembrolizumabJAMA Oncology, 2020
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in SarcomasJAMA Oncology, 2018
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010